All In Biotech

Drug Trial Radar · NCT06023602

Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone(GnRH)Antagonist Protocol in Women Undergoing IVF

Effectiveness of Generic Cetrorelix Acetate Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a GnRH Antagonist Protocol in Women Undergoing IVF: A Multicenter Non-inferiority, Randomised Controlled Trial

Last checked: Nov 19, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,338 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,338

Planned (sponsor's estimate)

Start

Feb 27, 2024

Primary completion

Dec 1, 2025

Study completion Dec 1, 2025

Sponsor

Lead sponsor
Northwest Women's and Children's Hospital, Xi'an, ShaanxiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 20 years, up to 42 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare the clinical outcomes using different cetrorelix acetate in the context of a GnRH antagonist protocol for ovarian stimulation in women undergoing IVF or intracytoplasmic sperm injection(ICSI) treatment.The main question it aims to answer is whether the generic cetrorelix acetate is non-inferior to the reference product in the GnRH antagonist based protocol for women undergoing IVF. Ovarian stimulation was achieved by several types of follicle-stimulating hormone(FSH) or by FSH combined with luteinizing hormone activity. Daily dose of generic cetrorelix acetate (0.25 mg SC) or original cetrorelix acetate (0.25 mg SC) will be administered when the lead follicle was 14 mm. When more than two follicles reached 17 mm, oocyte maturation was triggered with 250 mcg of recombinant human chorionic gonadotropin.

Conditions

  • Infertility

Interventions

  • Generic cetrorelix acetateDrug

    Generic cetrorelix acetate (0.25 mg SC)

  • Reference cetrorelix acetateDrug

    reference cetrorelix acetate (0.25 mg SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative live birth rateTime frame: Through study completion, an average of 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • He Cai

    Xi'an, None Selected, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.